AU2015350241B2 - Onapristone extended-release compositions and methods - Google Patents

Onapristone extended-release compositions and methods Download PDF

Info

Publication number
AU2015350241B2
AU2015350241B2 AU2015350241A AU2015350241A AU2015350241B2 AU 2015350241 B2 AU2015350241 B2 AU 2015350241B2 AU 2015350241 A AU2015350241 A AU 2015350241A AU 2015350241 A AU2015350241 A AU 2015350241A AU 2015350241 B2 AU2015350241 B2 AU 2015350241B2
Authority
AU
Australia
Prior art keywords
onapristone
extended
release
pharmaceutical composition
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2015350241A
Other languages
English (en)
Other versions
AU2015350241A1 (en
Inventor
Stefan PRONIUK
Alexander ZUKIWSKI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Context Biopharma Inc
Original Assignee
Context Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Context Biopharma Inc filed Critical Context Biopharma Inc
Publication of AU2015350241A1 publication Critical patent/AU2015350241A1/en
Assigned to CONTEXT BIOPHARMA INC. reassignment CONTEXT BIOPHARMA INC. Request for Assignment Assignors: ARNO THERAPEUTICS, INC.
Application granted granted Critical
Publication of AU2015350241B2 publication Critical patent/AU2015350241B2/en
Priority to AU2021218093A priority Critical patent/AU2021218093A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2015350241A 2014-11-17 2015-11-16 Onapristone extended-release compositions and methods Ceased AU2015350241B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2021218093A AU2021218093A1 (en) 2014-11-17 2021-08-18 Onapristone Extended-Release Compositions And Methods

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462080868P 2014-11-17 2014-11-17
US62/080,868 2014-11-17
PCT/US2015/060940 WO2016081383A1 (en) 2014-11-17 2015-11-16 Onapristone extended-release compositions and methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021218093A Division AU2021218093A1 (en) 2014-11-17 2021-08-18 Onapristone Extended-Release Compositions And Methods

Publications (2)

Publication Number Publication Date
AU2015350241A1 AU2015350241A1 (en) 2017-05-04
AU2015350241B2 true AU2015350241B2 (en) 2021-05-20

Family

ID=56014429

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2015350241A Ceased AU2015350241B2 (en) 2014-11-17 2015-11-16 Onapristone extended-release compositions and methods
AU2021218093A Abandoned AU2021218093A1 (en) 2014-11-17 2021-08-18 Onapristone Extended-Release Compositions And Methods

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2021218093A Abandoned AU2021218093A1 (en) 2014-11-17 2021-08-18 Onapristone Extended-Release Compositions And Methods

Country Status (11)

Country Link
US (3) US10786461B2 (OSRAM)
EP (1) EP3247362A4 (OSRAM)
JP (1) JP6655075B2 (OSRAM)
KR (1) KR20170084086A (OSRAM)
CN (2) CN106999501B (OSRAM)
AU (2) AU2015350241B2 (OSRAM)
CA (1) CA2966753A1 (OSRAM)
HK (1) HK1246653A1 (OSRAM)
MX (1) MX391191B (OSRAM)
RU (1) RU2017112748A (OSRAM)
WO (1) WO2016081383A1 (OSRAM)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2966753A1 (en) 2014-11-17 2016-05-26 Arno Therapeutics, Inc. Onapristone extended-release compositions and methods
AU2016326657B2 (en) 2015-09-25 2019-10-24 Context Biopharma, Inc. Methods of making onapristone intermediates
CA3008422A1 (en) 2015-12-15 2017-06-22 Context Biopharma Inc. Amorphous onapristone compositions and methods of making the same
US20180148471A1 (en) 2016-11-30 2018-05-31 Arno Therapeutics, Inc. Methods for onapristone synthesis dehydration and deprotection

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143754A (en) * 1994-10-24 2000-11-07 Schering Aktiengesellschaft Competitive progesterone antagonist for demand-oriented female birth control
US20130018027A1 (en) * 2010-03-22 2013-01-17 Repros Therapeutics Inc. Compositions and methods for non-toxic delivery of antiprogestins
US20130029953A1 (en) * 2011-07-28 2013-01-31 Klaus Nickisch Progesterone antagonists
US20140271819A1 (en) * 2013-03-12 2014-09-18 Stefan Proniuk Onapristone polymorphic forms and methods of use

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3321826A1 (de) 1983-06-15 1984-12-20 Schering AG, 1000 Berlin und 4709 Bergkamen 13(alpha)-alkylgonane, deren herstellung und diese enthaltende pharmazeutische praeparate
ES533260A0 (es) 1983-06-15 1985-02-01 Schering Ag Procedimiento para la preparacion de 13a-alquilgonanos
US4780461A (en) 1983-06-15 1988-10-25 Schering Aktiengesellschaft 13α-alkyl-gonanes, their production, and pharmaceutical preparations containing same
US4742000A (en) 1986-05-02 1988-05-03 University Of Chicago Antibody to human progesterone receptor and diagnostic materials and methods
DE3630030A1 (de) 1986-09-01 1988-03-03 Schering Ag 13(alpha)-alkylgonan-(delta)(pfeil hoch)9(pfeil hoch)(pfeil hoch)((pfeil hoch)(pfeil hoch)1(pfeil hoch)1(pfeil hoch))(pfeil hoch)-5,10-epoxide
US4774236A (en) 1986-09-17 1988-09-27 Research Triangle Institute 17α-(substituted-methyl)-17β-hydroxy/esterified hydroxy steroids and pharmaceutical compositions containing them
IE60780B1 (en) 1987-01-23 1994-08-10 Akzo Nv New 11-aryl steroid derivatives
DE3822770A1 (de) 1988-07-01 1990-01-04 Schering Ag 13-alkyl-11ss-phenylgonane
US5283190A (en) 1989-07-31 1994-02-01 Traish Adbulmaged M Specific monoclonal antibodies against a defined epitope of progesterone receptor and methods for their use
DE4008584A1 (de) 1990-03-15 1991-09-26 Schering Ag Verfahren zur herstellung von zwischenprodukten fuer die antigestagensynthese (onapristonsynthese)
US5141961A (en) 1991-06-27 1992-08-25 Richrdson-Vicks Inc. Process for solubilizing difficulty soluble pharmaceutical actives
MX9301121A (es) 1992-03-02 1993-09-01 Schering Ag Metodo y equipo para la contracepcion oral y regulacion de la menstruacion con estrogeno/progestina/aniprogestina.
CN1053450C (zh) 1992-11-19 2000-06-14 北京第三制药厂 17位取代11β－取代芳香基－4,9－雌甾二烯类化合物的全合成法
DE4332283A1 (de) 1993-09-20 1995-04-13 Jenapharm Gmbh Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US5759577A (en) 1995-01-17 1998-06-02 American Home Products Corporation Controlled release of steroids from sugar coatings
US6900193B1 (en) 1996-05-01 2005-05-31 The United States Of America As Represented By The Department Of Health And Human Services Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
IL122740A (en) 1997-01-15 2003-09-17 Akzo Nobel Nv 16-hydroxy-11-(substituted phenyl)-estra-9,4-diene derivatives, their preparation and pharmaceutical compositions containing them
US5962444A (en) 1998-05-29 1999-10-05 Research Triangle Institute 17β-nitro-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
US6537584B1 (en) 1999-11-12 2003-03-25 Macromed, Inc. Polymer blends that swell in an acidic environment and deswell in a basic environment
IL152656A0 (en) 2000-05-19 2003-06-24 Genentech Inc Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
US6750015B2 (en) 2000-06-28 2004-06-15 Kathryn B. Horwitz Progesterone receptor-regulated gene expression and methods related thereto
UY26966A1 (es) 2000-10-18 2002-06-20 Schering Ag Uso de antiprogestinas para la inducción de apoptosis en una célula
US7381976B2 (en) 2001-03-13 2008-06-03 Triton Thalassic Technologies, Inc. Monochromatic fluid treatment systems
AUPR546801A0 (en) 2001-06-05 2001-06-28 Commonwealth Scientific And Industrial Research Organisation Recombinant antibodies
US7105642B2 (en) 2001-08-03 2006-09-12 Cell Signalling Technology, Inc. Monoclonal antibodies specific for phosphorylated estrogen receptor alpha (Ser118) and uses thereof
US20040121304A1 (en) 2001-12-21 2004-06-24 Ulrike Fuhrmann Method for screening for progesterone receptor isoform-specific ligands and for tissue-selective progesterone receptor ligands
US20060111577A1 (en) 2003-02-28 2006-05-25 Kim Hyun K Method for preparing 17 alpha-acetoxy-11beta-(4-n,n-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione, intermediates thereof, and methods for the preparation of such intermediates
US20040265371A1 (en) 2003-06-25 2004-12-30 Looney Dwayne Lee Hemostatic devices and methods of making same
US7247625B2 (en) * 2003-10-09 2007-07-24 Wyeth 6-amino-1,4-dihydro-benzo[d][1,3] oxazin-2-ones and analogs useful as progesterone receptor modulators
KR101229701B1 (ko) 2004-07-09 2013-02-05 라보라토이레 에이치알에이 파르마 프로게스테론 수용체 조절제를 함유하는 서방형 조성물
JP5184087B2 (ja) 2004-09-22 2013-04-17 トリパス イメージング， インコーポレイテッド ガンの予後のためのマーカー候補を分析および最適化するための方法およびコンピュータープログラム製品
EP1874732A1 (en) 2005-04-20 2008-01-09 Pfizer Limited Pyrazole derivatives as progesterone receptor antagonists
JP2009519710A (ja) 2005-12-16 2009-05-21 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 遺伝子発現調節エレメントのハイスループットでの特徴付けのための機能性アレイ
US20070167971A1 (en) 2006-01-17 2007-07-19 Raymond Huey Devices and methods for promoting the formation of blood clots in esophageal varices
US20070166372A1 (en) 2006-01-19 2007-07-19 Mai De Ltd. Preparation of solid coprecipitates of amorphous valsartan
WO2007098381A2 (en) 2006-02-17 2007-08-30 Janssen Pharmaceutica N.V. 11-phosphorous steroid derivatives useful as progesterone receptor modulators
DE102006054535A1 (de) 2006-11-15 2008-05-21 Bayer Schering Pharma Aktiengesellschaft Progesteronrezeptorantagonisten
CN101668739A (zh) 2007-04-24 2010-03-10 帝斯曼知识产权资产管理有限公司 用于制造前维生素d的光化学方法
CA2596204C (en) 2007-08-07 2019-02-26 Historx, Inc. Method and system for determining an optimal dilution of a reagent
WO2009025759A1 (en) 2007-08-17 2009-02-26 Progenics Pharmaceuticals (Nevada), Inc. Tight junction proteins associated with infection and entry of hepatitis c virus (hcv), methods and uses thereof
EP3733161A1 (en) * 2007-10-12 2020-11-04 Novartis AG Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators
EP2075246A1 (en) 2007-12-27 2009-07-01 M. J. Institute of Research A process for preparation of amorphous form of atorvastatin hemi-calcium salt
CN101939009B (zh) 2008-02-05 2013-07-17 哈博生物科学公司 药学固体形式
TWI539953B (zh) 2008-04-28 2016-07-01 瑞波若斯治療學公司 用於治療乳癌之組成物和方法
TW201002736A (en) 2008-04-28 2010-01-16 Repros Therapeutics Inc Compositions and methods for treating progesterone-dependent conditions
US8744695B2 (en) 2009-03-27 2014-06-03 Komatsu Ltd. Fuel consumption saving control device for work vehicle and fuel consumption saving method for work vehicle
WO2010126590A1 (en) 2009-04-27 2010-11-04 Cold Spring Harbor Laboratory Ptp1b inhibitors
US20110003753A1 (en) 2009-06-01 2011-01-06 Samuel Waxman Cancer Research Foundation COMPOSITIONS AND METHODS FOR DISRUPTING THE FUNCTION OF THE TRANSCRIPTIONAL REPRESSOR COMPONENT Sin3A-PAH2 DOMAIN TO INDUCE DIFFERENTIATION AND GROWTH INHIBITION IN BREAST CANCER
EP2454266B1 (en) 2009-07-15 2013-07-10 Cell Therapeutics, Inc. 9e-15-(2-pyrrolidin-1-yl-ethoxy)-7,12,25-trioxa-19,21,24-triaza- tetracyclo[18.3.1.1(2,5).1(14)18)]hexacosa-1(24),2,4,9,14,16,18(26),20,22-nonaene citrate salt
US20110293511A1 (en) 2009-09-29 2011-12-01 Terrance Grant Johns Specific binding proteins and uses thereof
US8261855B2 (en) * 2009-11-11 2012-09-11 Flanders Electric, Ltd. Methods and systems for drilling boreholes
ES2780156T3 (es) 2009-12-15 2020-08-24 Pfizer Composiciones terapéuticas de nanopartículas poliméricas con alta temperatura de transición vítrea o copolímeros de alto peso molecular
DK2638163T3 (en) 2010-11-12 2017-07-24 Massachusetts Gen Hospital POLYCOMB-ASSOCIATED NON-CODING RNAs
JP6143675B2 (ja) 2010-12-16 2017-06-07 セルジーン コーポレイション 難溶性薬物の制御放出経口剤形及びその使用
EP2655621B1 (en) 2010-12-20 2018-05-23 The General Hospital Corporation Polycomb-associated non-coding rnas
JP2014510080A (ja) 2011-03-09 2014-04-24 セントローズ， エルエルシー 細胞外標的化薬物複合体
CA2829593A1 (en) * 2011-03-11 2012-09-20 Celgene Corporation Use of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl)piperidine-2,6-dione in treatment of immune-related and inflammatory diseases
US9618512B2 (en) 2011-04-15 2017-04-11 J-Pharma Co., Ltd. Biomarker for breast cancer
JP6276176B2 (ja) 2011-05-13 2018-02-07 ガニメド ファーマシューティカルズ ゲーエムベーハー 癌の治療のための抗体
EP2763680A4 (en) 2011-10-04 2015-05-20 Invivis Pharmaceuticals Inc METHODS AND SYSTEMS FOR IDENTIFYING AND TREATING ANTIPROGESTIN-SENSITIVE TUMORS
US10039806B2 (en) 2011-12-08 2018-08-07 Fundacion Sales Methods and compositions for treating antiprogestin-resistant cancers
US20130338016A1 (en) 2012-04-17 2013-12-19 Vala Sciences, Inc. Method For Integrated Pathology Diagnosis And Digital Biomarker Pattern Analysis
RU2014147625A (ru) 2012-04-27 2016-06-20 Реджентс Оф Зэ Юниверсити Оф Миннесота Прогнозирование рака молочной железы, предсказание подтипа прогестероновых рецепторов и предсказание ответа на лечение антипрогестином на основании генной экспрессии
CN104619343A (zh) 2012-07-24 2015-05-13 雪松-西奈医学中心 一种检测肺癌患者化疗抗性的新方法
WO2014093918A1 (en) 2012-12-13 2014-06-19 Warsaw Orthopedic, Inc. Compositions and methods comprising polyethylene glycol and magnesium for treatment of neuronal injury
US20140363425A1 (en) 2013-03-13 2014-12-11 J. Dinny Graham Systems and methods for identifying cancers having activated progesterone receptors
US9096641B2 (en) 2013-06-05 2015-08-04 Evestra, Inc. Imidazolyl progesterone antagonists
CN103483449A (zh) 2013-08-20 2014-01-01 东北农业大学 两种scFv抗体、其编码基因及其在制备治疗或预防鸡传染性法氏囊病制剂中的应用
WO2015157343A1 (en) 2014-04-08 2015-10-15 Arno Therapeutics, Inc. Systems and methods for identifying progesterone receptor subtypes
CA2966753A1 (en) 2014-11-17 2016-05-26 Arno Therapeutics, Inc. Onapristone extended-release compositions and methods
EP3273983B1 (en) 2015-03-23 2021-05-05 Evestra, Inc. Novel cytotoxic agents that preferentially target leukemia inhibitory factor (lif) for the treatment of malignancies and as new contraceptive agents
AU2016326657B2 (en) 2015-09-25 2019-10-24 Context Biopharma, Inc. Methods of making onapristone intermediates
CA3008422A1 (en) 2015-12-15 2017-06-22 Context Biopharma Inc. Amorphous onapristone compositions and methods of making the same
WO2017165315A1 (en) 2016-03-21 2017-09-28 Arno Therapeutics, Inc. Onapristone metabolite compositions and methods
CA3022961A1 (en) 2016-05-02 2017-11-09 Tetragenetics, Inc. Anti-kv1.3 antibodies, and methods of production and use thereof
WO2018067198A1 (en) 2016-10-03 2018-04-12 The Regents Of The University Of California Inhibitory antibodies and methods of use thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143754A (en) * 1994-10-24 2000-11-07 Schering Aktiengesellschaft Competitive progesterone antagonist for demand-oriented female birth control
US20130018027A1 (en) * 2010-03-22 2013-01-17 Repros Therapeutics Inc. Compositions and methods for non-toxic delivery of antiprogestins
US20130029953A1 (en) * 2011-07-28 2013-01-31 Klaus Nickisch Progesterone antagonists
US20140271819A1 (en) * 2013-03-12 2014-09-18 Stefan Proniuk Onapristone polymorphic forms and methods of use

Also Published As

Publication number Publication date
CN106999501A (zh) 2017-08-01
WO2016081383A1 (en) 2016-05-26
EP3247362A1 (en) 2017-11-29
JP2017537883A (ja) 2017-12-21
US20230157960A1 (en) 2023-05-25
US20160166583A1 (en) 2016-06-16
RU2017112748A3 (OSRAM) 2019-06-26
MX2017005163A (es) 2018-01-18
CA2966753A1 (en) 2016-05-26
US20210220279A1 (en) 2021-07-22
US10786461B2 (en) 2020-09-29
AU2015350241A1 (en) 2017-05-04
KR20170084086A (ko) 2017-07-19
CN106999501B (zh) 2021-08-13
CN113559075A (zh) 2021-10-29
EP3247362A4 (en) 2018-10-10
HK1246653A1 (zh) 2018-09-14
US11672762B2 (en) 2023-06-13
AU2021218093A1 (en) 2021-09-09
MX391191B (es) 2025-03-21
JP6655075B2 (ja) 2020-02-26
RU2017112748A (ru) 2018-12-19

Similar Documents

Publication Publication Date Title
US20230157960A1 (en) Onapristone extended-release compositions and methods
Nguyen et al. Evaluation of the effect of food and gastric pH on the single‐dose pharmacokinetics of cabozantinib in healthy adult subjects
CN103648487B (zh) 药物递送系统
US20220323446A1 (en) Sotorasib dosing regimen
JP2024519060A (ja) ソトラシブ投与レジメン
US20230270744A1 (en) Methods of Administering Elagolix
MX2007012081A (es) Tableta que contiene hormonas esteroides.
US20250017932A1 (en) Methods of Administering Elagolix
HK40062842A (en) Onapristone extended-release compositions and methods
WO2023049363A1 (en) Sotorasib and afatinib for treating cancer comprising a kras g12c mutation
WO2022261025A1 (en) Methods of treating cancer with a combination of sotorasib and trametinib
CN114340625A (zh) 用雌激素受体-α抑制剂的口服剂型治疗癌症的方法
TW202444376A (zh) 治療癌症之方法
TW202206074A (zh) 藥物配製物
WO2024005634A1 (en) Anti-angiogenic therapy as treatment for benign uterine disorders

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: CONTEXT BIOPHARMA INC.

Free format text: FORMER APPLICANT(S): ARNO THERAPEUTICS, INC.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired